U.S. market Closed. Opens in 2 days 6 hours 8 minutes

QURE | uniQure N.V. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 5.71 - 5.98
52 Week Range 3.73 - 11.35
Beta 0.93
Implied Volatility 108.88%
IV Rank 67.43%
Day's Volume 511,338
Average Volume 695,860
Shares Outstanding 48,743,100
Market Cap 281,735,118
Sector Healthcare
Industry Biotechnology
IPO Date 2014-02-05
Valuation
Profitability
Growth
Health
P/E Ratio -1.17
Forward P/E Ratio N/A
EPS -4.95
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 480
Country Netherlands
Website QURE
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
*Chart delayed
Analyzing fundamentals for QURE we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very good and Health is very weak. For more detailed analysis please see QURE Fundamentals page.

Watching at QURE technicals we can see that long-term trend is bullish, while middle-term trend is bearish, as well as bearish short-term trend. More technicals details can be found on QURE Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙